PERtuzumab-trastuzumab plus lEetrozoLe In endocrine Sensitive breast cancer: a phase II neoAdjuvant study

Trial Profile

PERtuzumab-trastuzumab plus lEetrozoLe In endocrine Sensitive breast cancer: a phase II neoAdjuvant study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Letrozole
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Therapeutic Use
  • Acronyms PER-ELISA
  • Most Recent Events

    • 16 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 16 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Oct 2017.
    • 17 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top